Dehydromonocrotaline is a mitochondrial respiratory chain complex I NADH oxidase inhibitor, with a IC50 of 62.06 µM and a Ki of 8.1 µM in rats. Dehydromonocrotaline exerts non-competitive inhibitory effects by modifying cysteine thiol groups on complex I, and does not bind to the NADH-binding site. Dehydromonocrotaline dissipates mitochondrial membrane potential and reduces ATP levels. Dehydromonocrotaline can be used in studies related to hepatotoxicity, pulmonary hypertension and liver tumors[1][2][3].
Molekulargewicht:
323.34
CAS Nummer:
[23291-96-5]
Formel:
C16H21NO6
Target-Kategorie:
Endogenous Metabolite
Anwendungsbeschreibung:
MCE Product type: Natural Products
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten